Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Ratings for Johnson & Johnson (NYSE:JNJ) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ...